CLINICAL TRIALS PROFILE FOR ABEMACICLIB
✉ Email this page to a colleague
All Clinical Trials for abemaciclib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01394016 ↗ | A Phase 1 Study of LY2835219 In Participants With Advanced Cancer | Active, not recruiting | Eli Lilly and Company | Phase 1 | 2009-12-07 | The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population. |
| NCT01655225 ↗ | A Study of LY3023414 in Participants With Advanced Cancer | Active, not recruiting | Eli Lilly and Company | Phase 1 | 2012-07-31 | The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma. |
| NCT01739309 ↗ | Study of LY2835219 for Mantle Cell Lymphoma | Active, not recruiting | Eli Lilly and Company | Phase 2 | 2013-03-20 | The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma. |
| NCT01913314 ↗ | A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | 2013-08-01 | This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon [^14C]. [^14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered. In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected. This study will last about 3 weeks for each participant, not including screening. |
| NCT02014129 ↗ | A Study of LY2835219 in Japanese Participants With Advanced Cancer | Completed | Eli Lilly and Company | Phase 1 | 2013-12-18 | The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer. |
| NCT02057133 ↗ | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | Active, not recruiting | Eli Lilly and Company | Phase 1 | 2014-03-10 | This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for abemaciclib
Condition Name
Clinical Trial Locations for abemaciclib
Trials by Country
Clinical Trial Progress for abemaciclib
Clinical Trial Phase
Clinical Trial Sponsors for abemaciclib
Sponsor Name
